DEGRAW, JULI,MORIARTY, ANN,LETURCQ, DIDIER J.,JACKSON, MICHAEL R.,PETERSON, PER A.,HEISKALA, MARJA
申请号：
CA2438754
公开号：
CA2438754C
申请日:
2002.02.19
申请国别(地区):
CA
年份:
2014
代理人:
摘要：
T cell responses are often diminished in humans with a compromised immunesystem. We have developed a method to isolate, stimulate and expand naïvecytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors,capable of lysing tumor cells in vivo. This ex vivo protocol produces fullyfunctional effectors. Artificial antigen presenting cells (AAPCs； Drosophilamelanogaster) transfected with human HLA class I and defined accessorymolecules, are used to stimulate CD8+ T cells from both normal donors andcancer patients. The class I molecules expressed to a high density on thesurface of the Drosophila cells are empty, allowing for efficient loading ofmultiple peptides that results in the generation of polyclonal responsesrecognizing tumor cells endogenously expressing the specific peptides. Theresponses generated are robust, antigen-specific and reproducible if thepeptide epitope is a defined immunogen. This artificial antigen expressionsystem can be adapted to treat most cancers in a significant majority of thepopulation.
